SHL Telemedicine Ltd
LSE:0QMX

Watchlist Manager
SHL Telemedicine Ltd Logo
SHL Telemedicine Ltd
LSE:0QMX
Watchlist
Price: 19 CHF 24.35%
Market Cap: CHf274.9m

Wall St Price Targets

0QMX Price Targets Summary
SHL Telemedicine Ltd

There are no price targets for 0QMX.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
SHL Telemedicine Ltd Competitors:
Price Targets
SRFM
Surf Air Mobility Inc
352% Upside
BMRN
Biomarin Pharmaceutical Inc
71% Upside
AVAH
Aveanna Healthcare Holdings Inc
36% Upside
OGI
OrganiGram Holdings Inc
114% Upside
YUMC
Yum China Holdings Inc
41% Upside
SMMT
Summit Therapeutics Inc
81% Upside

Revenue
Forecast

1% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
1% / Year
Past Growth
1% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

Over the last 14 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 8 years is 1%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
36%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
36%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0QMX's stock price target?
Not Available

0QMX does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for SHL Telemedicine Ltd?
Projected CAGR
1%

Over the last 14 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 8 years is 1%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett